SIERRA RADIOPHARMACY LLC

Sierra Radiopharmacy LLC specializes in the manufacturing and supply of radiopharmaceuticals for clinical use in nuclear medicine, with deep expertise in GMP-compliant preparation, radiolabeling, and sterile compounding of diagnostic and therapeutic agents. The company operates under strict regulatory frameworks to produce isotopic pharmaceuticals such as technetium-99m and fluorodeoxyglucose, tailored for imaging and treatment protocols in oncology, cardiology, and neurology. Their technical proficiency includes radiological safety, dose calibration, quality control testing, and just-in-time delivery systems critical for short-lived isotopes. A key differentiator is their ability to maintain consistent, on-demand production cycles aligned with the operational tempo of VA medical facilities, ensuring uninterrupted access to time-sensitive radiopharmaceuticals. The contractor maintains a sustained relationship with the Department of Veterans Affairs, consistently supporting the Reno Health Care System through direct supply contracts for radiopharmaceuticals and related logistics. Their work involves fulfilling IDIQ requirements, managing fund reallocations, and ensuring continuity of care for veteran patients requiring nuclear medicine services. This recurring engagement reflects a trusted, mission-critical partnership built on reliability and regulatory adherence. Sierra Radiopharmacy’s primary industry focus is pharmaceutical preparation manufacturing under NAICS 325412, positioning them as a niche provider in the federal nuclear medicine supply chain. They serve a specialized vertical within the broader healthcare sector, focusing exclusively on radiopharmaceuticals rather than general pharmaceuticals, distinguishing them from broader drug manufacturers. As a limited-liability entity based in Reno, Nevada, Sierra Radiopharmacy LLC operates as a small, focused supplier with no federal certifications on record. Their geographic location enables efficient regional distribution to Western U.S. VA facilities, reinforcing their role as a localized but mission-critical partner in the federal radiopharmaceutical ecosystem.